Showing 1831-1840 of 5771 results for "".
- Glaukos Announces Clinical Milestone of 200 Peer-Reviewed Publications on iStent Technologieshttps://modernod.com/news/glaukos-announces-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies/2479463/Glaukos announced a clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent technologies around the world. This achievement represents the largest, most diverse and longest-term body of clinical data for any MIGS procedure, according to Glau
- AAO: Proof of COVID-19 Vaccination Required for All Registrants Attending Annual Meeting in New Orleanshttps://modernod.com/news/aao-proof-of-covid-19-vaccination-required-for-all-registrants-attending-annual-meeting-in-new-orleans/2479461/The American Academy of Ophthalmology’s board of trustees has decided that proof of COVID-19 vaccination will be required for all registrants attending the Academy’s annual meeting in New Orleans. Every AAO 2021 attendee, all Academy staff, exhibitors, and guests will be required to
- Eyeque Announces Series C Closing With More Than $57 Million in Capital Raisedhttps://modernod.com/news/eyeque-announces-series-c-closing-with-more-than-57-million-in-capital-raised/2479459/EyeQue announced that they have closed a Series C round and have raised more than $57 million in capital since the company was founded in 2015. EyeQue aims to bring affordable vision correction with their smartphone vision tests. The company has developed a suite of at-
- Novartis Announces Positive Results From Phase 3 Trials of Beovu in DME, Including Dosing Intervals Up to 16 Weekshttps://modernod.com/news/novartis-announces-positive-results-from-phase-3-trials-of-beovu-in-dme-including-dosing-intervals-up-to-16-weeks/2479452/Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evalu
- Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-publication-of-positive-phase-1-clinical-data-evaluating-thr-687-for-treatment-of-dme/2479451/Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of t
- Oyster Point Pharma Announces License Agreement With Ji Xing Pharmaceuticals in Greater Chinahttps://modernod.com/news/oyster-point-pharma-announces-license-agreement-with-ji-xing-pharmaceuticals-in-greater-china/2479438/Oyster Point Pharma announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for the treatment of signs and symptoms of dry eye disease for patients in Greater Chi
- Heru Announces Commercial Availability of re:Vive in Partnership With Vision Sourcehttps://modernod.com/news/heru-launches-commercial-availability-of-revive-in-partnership-with-vision-source/2479437/Heru announced, in partnership with its worldwide launch partner Vision Source, the commercial availability of re:Vive, its wearable diagnostics and visual field application. re:Vive by Heru is a wearable porta
- Rayner Announces 1,000 IOLs Recorded on RayPRO Digital Platformhttps://modernod.com/news/rayner-announces-1000-iols-recorded-on-raypro-digital-platform/2479436/Rayner announced that it has achieved the milestone figure of 1,000 intraocular lenses recorded on RayPRO, its digital patient reported outcomes platform. Launched at ASCRS in 2019 for ophthalmic surgeons who perform cataract procedures, RayPRO is a web-based and mobile digital platform th
- Topcon Announces New Executive Appointmentshttps://modernod.com/news/topcon-announces-new-executive-appointments/2479425/Topcon Healthcare announced the appointment of several new members to the US executive team, as well as the promotion of key employees. Effective October 1, 2021, Peter Larsen will become the President of Topcon Medical Systems, succeeding John Fujita, who will be returning to Japan for a
- RxSight Announces Pricing of Initial Public Offeringhttps://modernod.com/news/rxsight-announces-pricing-of-initial-public-offering/2479423/RxSight announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16 per share. The gross proceeds to RxSight from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and